IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 80,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 80,000 shares of the stock in a transaction on Friday, May 23rd. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $80,000.00. Following the acquisition, the insider directly owned 452,825 shares in the company, valued at approximately $452,825. This trade represents a 21.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

NASDAQ:IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The stock’s fifty day moving average price is $0.73 and its two-hundred day moving average price is $0.95. The company has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. On average, analysts expect that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On IRIDEX

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Weber Capital Management LLC ADV purchased a new stake in IRIDEX in the second quarter valued at approximately $206,616. United Capital Financial Advisors LLC bought a new stake in IRIDEX during the second quarter valued at approximately $41,000. Diversify Advisory Services LLC purchased a new position in IRIDEX in the 2nd quarter worth approximately $30,000. Diversify Wealth Management LLC purchased a new position in IRIDEX in the 1st quarter worth approximately $35,000. Finally, Bank of New York Mellon Corp bought a new position in shares of IRIDEX in the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 20.10% of the company’s stock.

Key IRIDEX News

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.